INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5901, 29824, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5902, 33618, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5903, 33619, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5904, 33620, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5905, 473, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5906, 475, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5907, 476, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5908, 478, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5909, 479, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5910, 7923, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5911, 7924, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5912, 16720, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5913, 16721, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5914, 16722, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5915, 17206, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5916, 17207, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5917, 17243, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5918, 18026, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5919, 22273, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5920, 22513, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5921, 22514, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5922, 22516, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5923, 24668, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5924, 25735, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5925, 29824, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5926, 33618, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5927, 33619, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5928, 33620, 'Memantine', 'Kidney Diseases', 'Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine.  Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract.  Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5929, 0, 'Meperidine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5930, 0, 'Meperidine', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5931, 0, 'Meperidine', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5932, 0, 'Meperidine', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5933, 0, 'Meperidine', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5934, 0, 'Meperidine', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5935, 0, 'Meperidine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5936, 0, 'Meperidine', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5937, 0, 'Meperidine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5938, 0, 'Meperidine', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5939, 0, 'Meperidine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5940, 0, 'Meperidine', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5941, 0, 'Meperidine', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5942, 0, 'Meperidine', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5943, 0, 'Meperidine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5944, 0, 'Meperidine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5945, 0, 'Meperidine', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5946, 0, 'Metamfetamine', 'Cardiovascular Diseases', 'The use of amphetamines and amphetamine-like drugs is contraindicated in patients with advanced arteriosclerosis, symptomatic or unstable cardio- or cerebrovascular disease, moderate to severe hypertension, or hyperthyroidism.  Like other sympathomimetic amines, amphetamines may cause cardiovascular adverse effects such as palpitation, tachycardia, cardiac arrhythmias, and elevation of blood pressure.  Rarely, cardiomyopathy manifested as ventricular hypertrophy and/or congestive heart failure has been reported during chronic amphetamine use.  In addition, sudden death has been reported in association with amphetamine therapy at usual dosages in children with structural cardiac abnormalities.  In general, amphetamines should not be used in patients with structural cardiac abnormalities.  If not otherwise contraindicated, therapy with amphetamines should be administered cautiously in patients with a current or past history of cardiovascular or cerebrovascular disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5947, 0, 'Metamfetamine', 'Glaucoma', 'The use of amphetamines and amphetamine-like drugs is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles.  Like other sympathomimetic amines, amphetamines can induce transient mydriasis.  In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma.  If possible, these agents should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5948, 0, 'Metamfetamine', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5949, 0, 'Metamfetamine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5950, 0, 'Metamfetamine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5951, 0, 'Metamfetamine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5952, 0, 'Metamfetamine', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5953, 0, 'Metamfetamine', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5954, 0, 'Metamfetamine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5955, 0, 'Metamfetamine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5956, 0, 'Metamfetamine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5957, 0, 'Metamfetamine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5958, 0, 'Metamfetamine', 'Diabetes Mellitus, Type 2', 'Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight.  Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5959, 8042, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5960, 9733, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5961, 9736, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5962, 14538, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5963, 22328, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5964, 24686, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5965, 24687, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5966, 24689, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5967, 26486, 'Mesalazine', 'Liver Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease.  Liver function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5968, 8042, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5969, 9733, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5970, 9736, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5971, 14538, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5972, 22328, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5973, 24686, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5974, 24687, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5975, 24689, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5976, 26486, 'Mesalazine', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5977, 5097, 'Arformoterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Arformoterol inhalation solution is not indicated to treat asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5978, 5105, 'Arformoterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Arformoterol inhalation solution is not indicated to treat asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5979, 8100, 'Arformoterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Arformoterol inhalation solution is not indicated to treat asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5980, 14533, 'Arformoterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Arformoterol inhalation solution is not indicated to treat asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5981, 15524, 'Arformoterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Arformoterol inhalation solution is not indicated to treat asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5982, 19320, 'Arformoterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Arformoterol inhalation solution is not indicated to treat asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5983, 19322, 'Arformoterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Arformoterol inhalation solution is not indicated to treat asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5984, 30108, 'Arformoterol', 'Asthma', 'Long acting beta- 2 adrenergic antagonists (LABA) increase the risk of asthma related death.  Arformoterol inhalation solution is not indicated to treat asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5985, 5097, 'Arformoterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5986, 5105, 'Arformoterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5987, 8100, 'Arformoterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5988, 14533, 'Arformoterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5989, 15524, 'Arformoterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5990, 19320, 'Arformoterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5991, 19322, 'Arformoterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5992, 30108, 'Arformoterol', 'Hepatic Insufficiency', 'Some long acting beta- 2 adrenergic agonists (LABA) such as arformoterol and olodaterol should be used with caution in patients with hepatic impairment due to increased systemic exposure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5993, 5097, 'Arformoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5994, 5105, 'Arformoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5995, 8100, 'Arformoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5996, 14533, 'Arformoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5997, 15524, 'Arformoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5998, 19320, 'Arformoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5999, 19322, 'Arformoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6000, 30108, 'Arformoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', '', 'DDInter', 0);
